Introduction: Pulpectomy is the treatment alternative in rescuing the pulpally involved carious primary teeth. Various obturating materials are being used to conserve an infected deciduous dentition. The present study documents the use of a novel obturating material in primary molars due to the disadvantages associated with of the currently used materials. Objective: To evaluate clinically and radiographically the success rate of the mixture of zinc oxide powder and nanohydroxyapatite with saline as an obturating material in primary molars and also to compare its efficiency with Endoflas. Material and Methods: Thirty pulpectomy indicated primary molars were randomly divided into two equal groups; Group I (mixture of zinc oxide powder and nanohydroxyapatite with saline) and Group II (Endoflas FS). The teeth were evaluated using various clinical and radiographic criteria at 3, 6 and 9-month intervals. The obtained results were statistically analyzed (P <0.05). Results: The overall present study findings revealed 100% clinical success in both the groups. Whereas radiographically, success reported was 66% for Group I and 100% for Group II at the end of 9 months follow-up. The difference in the radiographic success rate between the two groups was statistically significant (P <0.05). Conclusion: Endoflas FS had demonstrated high success rate both clinically and radiographically when compared to the novel combination of a mixture of zinc oxide powder and nanohydroxyapatite with saline as obturating material.KeywordsEndoflas; Mixture of zinc oxide and nanohydroxyapatite; Obturating material; Pulpectomy; Primary molars; Endoflas.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.